Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

In this article, we will look at the 10 Best Mid Cap Biotech Stocks to Buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated?

Can an AI tool be better than the industry standard at predicting which cancer patients will respond to treatment? Will drug companies feel the impacts of new cuts at the Department of Health and ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

At close: 28 March at 16:00:00 GMT-4 ...